Salts of an epidermal growth factor receptor kinase inhibitor
The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same.
1. Compound 2:
wherein:
n is 1; and
X is hydrobromic acid;
wherein the compound is a Form I hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
2. The compound of claim 1 , wherein the compound is a Form I hydrobromic acid salt characterized by two or more peaks in a powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
3. The compound of claim 2 , wherein the compound is a Form I hydrobromic acid salt characterized by three or more peaks in a powder X-ray diffraction pattern selected from those at about 17.39, about 19.45, about 21.41, about 23.56 and about 27.45 degrees 2-theta.
4. The compound of claim 3 , wherein the compound is a Form I hydrobromic acid salt characterized by substantially all of the peaks in a X-ray powder diffraction pattern selected from those at about 9.84, 15.62, 17.39, 19.45, 20.69, 21.41, 22.38, 23.56, 25.08 and 27.45 degrees 2-theta.
5. The compound of claim 4 , wherein the compound is a Form I hydrobromic acid salt characterized by substantially all of the peaks in a X-ray powder diffraction pattern selected from those at about
°2-Theta
3.17
3.48
3.79
5.60
7.92
8.35
9.84
11.52
14.10
15.23
15.62
16.73
17.39
18.23
19.45
20.69
21.41
22.38
23.56
24.65
25.08
26.26
27.45
28.50
29.06
29.77
29.94
30.66
31.35
32.45
32.82
34.18
34.80
35.35
36.01
36.82
37.61
37.96
38.55
39.13
40.04
40.64
40.86
41.03
41.39
42.16
42.48
42.78
44.28
45.34
45.59
46.57
47.20
47.51.
6. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
7. Compound 2:
wherein:
n is 1; and
X is hydrobromic acid;
wherein the compound is a Form III hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 6.79, about 13.36, about 19.93, about 20.89, about 21.90, about 22.70, about 22.91 and about 26.34 degrees 2-theta.
8. A composition comprising the compound of claim 7 and a pharmaceutically acceptable carrier or excipient.
9. Compound 2:
wherein:
n is 1; and
X is hydrobromic acid;
wherein the compound is a Form IV hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 6.45, about 12.96, about 19.38, about 19.79, about 21.37 and about 21.58 degrees 2-theta.
10. A composition comprising the compound of claim 9 and a pharmaceutically acceptable carrier or excipient.
11. Compound 2:
wherein:
n is 1; and
X is hydrobromic acid;
wherein the compound is a Form V hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 6.17, about 6.99, about 12.50, about 14.14, about 17.72 and about 23.12 degrees 2-theta.
12. A composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier or excipient.
13. Compound 2:
wherein:
n is 1; and
X is hydrobromic acid;
wherein the compound is a Form VI hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 8.38, about 9.38, about 18.93, and about 21.58 degrees 2-theta.
14. A composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier or excipient.
15. Compound 2:
wherein:
n is 1; and
X is hydrobromic acid;
wherein the compound is a Form VII hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 15.91, about 19.10, about 19.53, about 20.24, about 22.64 and about 25.58 degrees 2-theta.
16. A composition comprising the compound of claim 15 and a pharmaceutically acceptable carrier or excipient.
17. Compound 2:
wherein:
n is 1; and
X is hydrobromic acid;
wherein the compound is a Form VIII hydrobromic acid salt characterized by one or more peaks in a powder X-ray diffraction pattern selected from those at about 8.79, about 11.13, about 19.97, about 21.31, about 21.56, about 25.30 and about 26.65 degrees 2-theta.
18. A composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier or excipient.
19. Compound 2:
wherein:
n is 2; and
X is benzenesulfonic acid;
wherein the compound is a hydrate having one or more peaks in a powder X-ray diffraction pattern selected from those at about 10.68, about 16.10, about 18.44 and about 22.36 degrees 2-theta.
20. A composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier or excipient.